CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.09B, above the global median of $1.15B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
2.09BUSDvs all stocks (USD)
Revenue (TTM)
833.10MUSDvs all stocks (USD)
Profit Margin
-41.68%Beta
1.67xvs all stocks
52-Week Change
898.30%vs all stocks
Market Capitalization
2.09BUSDvs all stocks (USD)
Enterprise Value
869.62MUSDvs all stocks (USD)
Forward P/E
-5.53xPrice to Sales (TTM)
0.4082xPrice to Book (MRQ)
0.3840xEnterprise to Revenue
1.04xEnterprise to EBITDA
4.13xGross Margin
55.86%Profit Margin
-41.68%Operating Margin
7.24%Return on Assets (TTM)
2.48%Return on Equity (TTM)
-33.04%Revenue (TTM)
833.10MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.31USDUpdated Jul 19, 2026Quarterly Revenue Growth
-6.40%Gross Profit (TTM)
419.18MUSDvs all stocks (USD)
EBITDA (TTM)
223.44MUSDvs all stocks (USD)
Net Income (TTM)
-347.20MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-9.05%Operating Cash Flow (TTM)
82.54MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-198.15MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
-1.35MUSDFY2024 · Dec 31, 2024Revenue
878.59MUSDFY2024 · Dec 31, 2024Cost of Goods Sold
434.65MUSDFY2024 · Dec 31, 2024Gross Profit
443.93MUSDFY2024 · Dec 31, 2024Operating Income
90.52MUSDvs all stocks (USD)
Pre-tax Income
-299.92MUSDFY2024 · Dec 31, 2024Income Tax Expense
41.94MUSDFY2024 · Dec 31, 2024Net Income
-341.86MUSDFY2024 · Dec 31, 2024EBIT
-245.16MUSDFY2024 · Dec 31, 2024EBITDA (Income Statement)
237.57MUSDFY2024 · Dec 31, 2024Selling, General & Administrative
353.41MUSDFY2024 · Dec 31, 2024Non-operating Interest Expense
54.76MUSDFY2024 · Dec 31, 2024EPS (Basic)
-0.9529USDFY2024 · Dec 31, 2024EPS (Diluted)
-0.9529USDFY2024 · Dec 31, 2024Basic Shares Outstanding
358.75MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
358.75MSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
-341.86MUSDFY2024 · Dec 31, 2024Minority Interests (P&L)
0.00USDFY2024 · Dec 31, 2024Operating Cash Flow
-29.68MUSDFY2024 · Dec 31, 2024Free Cash Flow
-128.73MUSDFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
87.80MUSDFY2024 · Dec 31, 2024Income Tax Paid
81.53MUSDFY2024 · Dec 31, 2024Interest Paid
52.56MUSDFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-341.86MUSDFY2024 · Dec 31, 2024Depreciation & Amortization
150.86MUSDFY2024 · Dec 31, 2024Stock-based Compensation
16.95MUSDFY2024 · Dec 31, 2024Other Non-cash Items
15.67MUSDFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-2.75MUSDFY2024 · Dec 31, 2024Change in Accounts Payable (CF)
-4.18MUSDFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
135.63MUSDFY2024 · Dec 31, 2024Capital Expenditures
-99.05MUSDFY2024 · Dec 31, 2024Net Acquisitions
-35.88MUSDFY2024 · Dec 31, 2024Other Investing Activity
1.67MUSDFY2024 · Dec 31, 2024Net Investing Cash Flow
-133.25MUSDFY2024 · Dec 31, 2024Long-term Debt Issuance
0.00USDFY2024 · Dec 31, 2024Long-term Debt Payments
-63.40MUSDFY2024 · Dec 31, 2024Other Financing Charges
-2.52MUSDFY2024 · Dec 31, 2024Net Financing Cash Flow
-65.93MUSDFY2024 · Dec 31, 2024Shares Outstanding
361.78MSharesUpdated Jul 19, 2026Float Shares
293.99MSharesUpdated Jul 19, 2026% Held by Insiders
13.42%vs all stocks
% Held by Institutions
10.18%vs all stocks
Total Cash (MRQ)
82.62MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.2280USDUpdated Jul 19, 2026Total Debt (MRQ)
505.37MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.5716xCurrent Ratio (MRQ)
2.69xBook Value per Share (MRQ)
2.45USDUpdated Jul 19, 2026Total Assets
1.99BUSDvs all stocks (USD)
Total Current Assets
357.51MUSDFY2024 · Dec 31, 2024Total Liabilities
1.04BUSDFY2024 · Dec 31, 2024Total Non-current Assets
1.63BUSDFY2024 · Dec 31, 2024Total Non-current Liabilities
840.17MUSDFY2024 · Dec 31, 2024Total Current Liabilities
197.97MUSDFY2024 · Dec 31, 2024Cash & Cash Equivalents
87.80MUSDFY2024 · Dec 31, 2024Accounts Receivable
40.26MUSDFY2024 · Dec 31, 2024Inventory
184.46MUSDFY2024 · Dec 31, 2024Accounts Payable
39.93MUSDFY2024 · Dec 31, 2024Short-term Debt
29.40MUSDFY2024 · Dec 31, 2024Long-term Debt
493.58MUSDFY2024 · Dec 31, 2024Other Non-current Liabilities
1.91MUSDFY2024 · Dec 31, 2024Common Stock (Book)
1.74BUSDFY2024 · Dec 31, 2024Retained Earnings
-783.61MUSDFY2024 · Dec 31, 2024Total Shareholders' Equity
950.82MUSDvs all stocks (USD)
52-Week Low
0.5280USDUpdated Jul 19, 202652-Week High
9.75USDUpdated Jul 19, 202652-Week Change
898.30%vs all stocks
Beta
1.67xvs all stocks
50-Day MA
1.34USDUpdated Jul 19, 2026200-Day MA
0.9239USDUpdated Jul 19, 2026Avg 10-Day Volume
259.73KSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.20MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.9900USDUpdated Jul 19, 2026Other Income / Expense
-335.68MUSDFY2024 · Dec 31, 2024Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.09B, above the global median of $1.15BNotable
Market cap (USD): 2,091,062,443Global Median: 1,146,734,693.424
Revenue is $833.1M, above the global median of $520.53MNotable
Revenue (USD): 833,097,024Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hanall Biopharma Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eris Lifesciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow